GPC3 and hepatocellular carcinoma: Considering the prevalence of GPC3 as a biomarker andtherapeutic target in HCC (Koksal etal. 2022, Wu etal. 2022), its presence in the top most candidate genes wasanticipated, confirming the validity of our approach.